Cargando…

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study

OBJECTIVES: To determine whether SLE patients with inflammatory joint symptoms and US synovitis/tenosyovitis achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objectives included identification of clinical features predicting US synovitis/tenosy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Khaled, Zayat, Ahmed S, Yusof, Md Yuzaiful Md, Dutton, Katherine, Teh, Lee Suan, Yee, Chee-Seng, D’Cruz, David, Ng, Nora, Isenberg, David, Ciurtin, Coziana, Conaghan, Philip G, Emery, Paul, Edwards, Christopher J, Hensor, Elizabeth M A, Vital, Edward M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566203/ https://www.ncbi.nlm.nih.gov/pubmed/33792659 http://dx.doi.org/10.1093/rheumatology/keab288

Ejemplares similares

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus
por: Mahmoud, Khaled, et al.
Publicado: (2019)

Early intervention in systemic lupus erythematosus: time for action to improve outcomes and health-care utilization
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2021)

Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2022)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2017)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
por: El‐Sherbiny, Yasser M., et al.
Publicado: (2020)

British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
por: Yee, Chee-Seng, et al.
Publicado: (2007)

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2018)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
por: Yee, Chee-Seng, et al.
Publicado: (2011)

Musculoskeletal sonography in juvenile systemic lupus erythematosus
por: Demirkaya, E, et al.
Publicado: (2008)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk
por: Robinson, George A., et al.
Publicado: (2022)

A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention
por: Jiao, Hanxiao, et al.
Publicado: (2022)

Flares in patients with systemic lupus erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2020)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

Plant-based dietary changes may improve symptoms in patients with systemic lupus erythematosus
por: Knippenberg, Aziyadé, et al.
Publicado: (2022)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
por: Pepple, Sophanit, et al.
Publicado: (2022)

Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach
por: Robinson, George A, et al.
Publicado: (2020)

The Impact of Vitamin D on the Immunopathophysiology, Disease Activity, and Extra-Musculoskeletal Manifestations of Systemic Lupus Erythematosus
por: Mak, Anselm
Publicado: (2018)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Mycophenolate mofetil in the treatment of lupus nephritis
por: Yong, Patrick FK, et al.
Publicado: (2008)

Current and emerging treatment options in the management of lupus
por: Jordan, Natasha, et al.
Publicado: (2016)

Imaging of musculoskeletal lymphoma
por: Lim, Chee Yeong, et al.
Publicado: (2013)

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity
por: Psarras, Antonios, et al.
Publicado: (2020)

Editorial: Cutting edge in systemic lupus erythematosus
por: D’Cruz, David P., et al.
Publicado: (2017)

The effect of relaxin on the musculoskeletal system
por: Dehghan, F, et al.
Publicado: (2014)

Topical calcineurin inhibitors in systemic lupus erythematosus
por: Lampropoulos, Christos E, et al.
Publicado: (2010)

Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

Towards Precision Medicine in Systemic Lupus Erythematosus
por: Lever, Elliott, et al.
Publicado: (2020)

RAB23 regulates musculoskeletal development and patterning
por: Hasan, Md. Rakibul, et al.
Publicado: (2023)

Ultrasound detects subclinical joint inflammation in the hands and wrists of patients with systemic lupus erythematosus without musculoskeletal symptoms
por: Ruano, Carina A, et al.
Publicado: (2017)

Antiphospholipid Antibodies in Inflammatory and Autoimmune Rheumatic and Musculoskeletal Diseases Beyond Lupus: A Systematic Review of the Available Evidence
por: El Hasbani, Georges, et al.
Publicado: (2021)

Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study
por: Bello, Natalia, et al.
Publicado: (2022)

Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up
por: Luo, Weike, et al.
Publicado: (2022)

Clinical observation: are nightmares a manifestation of neuropsychiatric lupus?
por: D’Cruz, David P, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6m02abf76so9sog21943l7tbdv